DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for sweet syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSweet syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for sweet syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
MEFV innate immunity regulator, pyrin (MEFV) — MEFV is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet dhldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4CG4 · 2.4 Å · ligand 2-AMINO-ETHANETHIOL (DHL). Experimental structure, not a prediction.
What the evidence adds up to
A 15-year-old girl with aplastic anaemia developed Sweet syndrome after seven months of recombinant granulocyte colony-stimulating factor (G-CSF) given on alternate days. The white blood cell count reached 10,000 per microlitre when a painful erythematous plaque appeared on the thigh. Antibiotics were ineffective and cultures were negative. Biopsy showed dermal infiltration by sheets of neutrophils. The lesion resolved when G-CSF was stopped and corticosteroids were started, then recurred when G-CSF was restarted. The authors concluded the syndrome was induced by G-CSF treatment.
A 47-year-old man with known Crohn’s disease presented with headache, fever and skin lesions resembling erythema nodosum. Cerebrospinal fluid showed neutrophil-predominant pleocytosis with negative cultures. Skin biopsy confirmed neutrophilic dermatosis compatible with Sweet syndrome. The patient recovered promptly without corticosteroids. The authors noted this association of neuro-Sweet syndrome with Crohn’s disease had not been previously reported.
A 58-year-old woman with cholestatic syndrome and weight loss had developed erythematous papules and blisters five months earlier. Histopathology showed neutrophilic dermatosis with oedema, fibrin, necrosis and elastosis. Hepatic cholangiocarcinoma was confirmed. Staging showed advanced tumour without curative options; the patient received palliative care and died within weeks. The authors concluded that neoplasia such as cholangiocarcinoma may be a later manifestation of Sweet syndrome.
A nationwide analysis of hospitalised patients using the 2015 Nationwide Inpatient Sample identified 89 patients with Sweet syndrome, representing 445 patients nationally. Of these, 26 (representing 130 patients) had concurrent cancer, giving a hospitalisation incidence of 0.00002 per 1000 patient-years. Among malignancy-related Sweet syndrome patients, 16 had acute myeloid leukaemia, 3 had non-Hodgkin lymphoma, and single cases included myelodysplastic syndrome, essential thrombocythaemia, and solid tumours. Mean age was 62.4 years; 38.4% were female; 88.5% were white. In-hospital mortality was 7.8%, mean length of stay 20.7 days, and mean total hospitalisation cost $45,520. Compared with non-malignancy-related Sweet syndrome, malignancy-related patients tended to be older (62.4 vs 52.9 years, P=0.06) and male (61.5% vs 41.3%, P=0.08), and had significantly higher costs (P=0.02). The authors noted this was the first national-level observational study. What remains missing is prospective data on treatment response, standardised diagnostic criteria for drug-induced versus paraneoplastic cases, and any controlled trial of interventions beyond case reports and retrospective series.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Pediatric Hematology/Oncology · 1996 · 42 citations
Sweet Syndrome in a Child with Aplastic Anemia Receiving Recombinant Granulocyte Colony-Stimulating Factor
AbstractPURPOSE: To elucidate the pathogenesis of Sweet syndrome, one patient with aplastic anemia was evaluated. PATIENT AND METHODS: A 15-year-old girl presented with intermittent fever and progressive pallor for 3 months after non-A, non-B, non-C hepatitis. Aplastic anemia was diagnosed and therapy was begun with recombinant granulocyte colony-stimulating factor (G-CSF), methylprednisolone pulse therapy, antilymphocyte globulin and cyclosporin A. There was only an increase in the neutrophil counts. We continued G-CSF therapy of 300 micrograms/m2 on alternate days for 7 months. At this time the white blood cell count was 10,000/microliters and the patient developed high-grade fever and a painful, erythematous, tender plaque (3 X 3 cm) on the left thigh. We diagnosed the lesion as a skin infection and stopped G-CSF therapy and started antibiotics. Cultures were negative. The lesion slowly resolved, G-CSF was restarted after 2 months, and 1 month later disseminated lesions occurred. Antibiotic therapy was not effective. RESULTS: Biopsy of the lesion demonstrated infiltration of the dermis by sheets of neutrophils. We stopped G-CSF and began corticosteroid therapy. The skin lesions resolved rapidly. CONCLUSION: We postulated that Sweet syndrome was induced by G-CSF treatment.
Journal of Medical Case Reports · 2009 · 10 citations · open access
A 47-year-old man with neuro-Sweet syndrome in association with Crohn's disease: a case report
AbstractINTRODUCTION: Sweet's syndrome is a multi-system inflammatory disorder characterised by painful skin lesions and aseptic neutrophilic infiltration of various organs. We describe a case of Sweet's syndrome with aseptic meningitis in association with Crohn's disease (neuro-Sweet syndrome). This association has never been previously reported. CASE PRESENTATION: A 47-year-old Caucasian male with known Crohn's disease presented with headache, fever and skin lesions resembling erythema nodosum. The cerebrospinal fluid revealed leukocyte pleocytosis and dominant neutrophils, but cultures were negative. A skin biopsy revealed neutrophilic dermatosis compatible with Sweet's disease. The patient made a prompt recovery without the use of corticosteroids. CONCLUSION: Because of its multisystem nature, Sweet's syndrome may present diagnostic difficulty to specialists. Correct diagnosis by skin biopsy will prompt appropriate treatment.
World Journal of Clinical Cases · 2020 · 4 citations · open access
Sweet syndrome as a paraneoplastic manifestation of cholangiocarcinoma: A case report
AbstractBACKGROUND: Sweet's syndrome, also known as acute febrile neutrophilic dermatosis, is a rare skin disorder that may be associated with cancer. CASE SUMMARY: A 58-year-old female presented with a cholestatic syndrome and significant weight loss three months before admission. Five months earlier, she had abruptly developed skin lesions with erythematous papules that evolved to erythematous blisters. Clinical evaluation and laboratory tests confirmed hepatic cholangiocarcinoma. Skin lesions histopathological findings showed neutrophilic dermatosis, massive edema, fibrin, necrosis, and elastosis. These results, in association with the macroscopic aspects of the findings, led to the diagnosis of paraneoplastic Sweet's syndrome due to cholangiocarcinoma. As staging was consistent with an advanced tumor without a cure perspective, we opted to perform percutaneous biliary drainage, and subsequently, palliative care. Eventually, after a few weeks, the patient died. CONCLUSION: In conclusion, the diagnosis of the underlying disease-causing Sweet's syndrome must be accurate, and patients need to be followed-up, as neoplasia such as cholangiocarcinoma may be a later manifestation.
A nationwide analysis of hospitalized patients with malignancy-related Sweet syndrome (MRSS).
Abstracte18742 Background: Sweet syndrome (SS) is rare but commonly associated with malignancy. Due to the lack of a national dataset, only institutional-level retrospective studies have been published. In the 4th quarter of 2015, Nationwide Inpatient Sample(NIS) started to employ the ICD-10-CM code which allows for exploration of the characteristics of SS patients with a nationally representative database. Methods: 89 patients with SS in the 4th quarter of 2015 were identified with the NIS, representing 445 patients nationally. Those with concurrent cancer were categorized as MRSS. The characteristics of MRSS patients were described and compared against patients with non-malignancy-related Sweet Syndrome (NMRSS). Results: Among all SS patients, 26 patients (representing 130 patients nationally) had cancer. The incidence rate of hospitalization for MRSS was 0.00002 per 1000 patient year. The mean age of MRSS patients was 62.4 years old. 38.4% of the patients were female, 88.5% were white, 15.4% had a low income and 84.6% was admitted to urban teaching hospitals. 7.8% of the patients died during the hospitalization with a mean length of stay of 20.7 days. The mean total hospitalization cost was 45520 US dollars. Among the patients with MRSS, 16 patients had AML, 3 had NHL, 1 had ET, 1 had MDS, 1 had prostate cancer, 1 had breast cancer, 1 had lung cancer, 1 had endometrium cancer and 1 had secondary malignancy of lung. No statistical significance was found in age, gender, race, income, hospital teaching/location status or length of stay between MRSS and NMRSS. However, MRSS patients tended to be older (62.4 vs 52.9-year-old, P = 0.06) and be male (61.5% vs 41.3%, P = 0.08). Total hospitalization cost of MRSS patients was higher (45520.0 vs 19720.4 US dollar, P = 0.02). Conclusions: To the best of our knowledge, this is the first observational study of SS at national level. Our study showed that MRSS represents around 30% of the nationwide patients. Sweet syndrome was more likely to occur in hematologic malignancies with AML being the most common cause. MRSS patients tended to be male and older, with hospitalization cost being significantly higher.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
